MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain on
available-for-sale securities
$294K
Comprehensive loss
-$34,305K
(54.39%↑ Y/Y)
Total other
comprehensive income
$294K
(-80.07%↓ Y/Y)
Interest income
$5,521K
Other income
(expense), net
$453K
Net loss
-$34,599K
(54.88%↑ Y/Y)
Total other income
(expense), net
$5,414K
(-20.28%↓ Y/Y)
License
$70,000K
Collaboration
$570K
Interest expense
$560K
(-44.22%↓ Y/Y)
Loss from operations
-$40,013K
(52.07%↑ Y/Y)
Total revenue
$70,570K
(81958.14%↑ Y/Y)
Total operating
expenses
$110,583K
(32.33%↑ Y/Y)
Research and development
$86,261K
(24.73%↑ Y/Y)
General and
administrative
$24,322K
(68.81%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)